Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

What Happened? Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 5.4% in the morning session after TD Cowen ...

On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.

While Bio-Techne stock has underperformed the broader market over the past year, analysts remain moderately bullish about its ...

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.

According to a Feb. 17, 2026, SEC filing, Hollow Brook Wealth Management LLC sold out its entire position in Bio-Techne (NASDAQ:TECH) during the fourth quarter of 2025. The fund divested 174,677 ...

Bio-Techne TECH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of 56 cents, which surpassed the Zacks Consensus Estimate by 9.8%. The bottom line improved from the year-ago ...

Bio-Techne’s (TECH Quick Quote TECH - Free Report) GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an ...

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck ...

Bio-Techne Corp. (TECH Quick Quote TECH - Free Report) recently launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the ...

Valued at a market cap of $9.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities.

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...